The company's platform utilizes vesicles derived from immune or stem cells to enable biotech and pharmaceutical companies to develop novel therapeutics that deliver various drugs to specific target tissues. This allows doctors to provide vesicle-based anticancer drugs to their patients. MDimune focuses on researching and developing BioDrone, an artificial exosome-based drug delivery platform that specifically delivers drugs to cancer cells. Founded in 2015 and based in Seoul, South Korea, MDimune aims to revolutionize the world through the development of new drugs and serve the needs of patients.